Estrogen Receptor-positive Breast Cancer Clinical Trials

72 clinical trials for Estrogen Receptor-positive Breast Cancer across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer — RECRUITING · PHASE2
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer — RECRUITING · PHASE2
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies — RECRUITING · PHASE2
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer — RECRUITING · PHASE2
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) — RECRUITING · PHASE2
• Breast Re-irradiation After Second Ipsilateral Lumpectomy — RECRUITING · NA
• Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer. — RECRUITING · NA
• Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) — RECRUITING · PHASE2
• Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer — RECRUITING · PHASE2
• (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca — ACTIVE_NOT_RECRUITING · PHASE2
• [18F]FES PET/CT in Endocrine Refractory Breast Cancer — TERMINATED · PHASE2
• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery — ACTIVE_NOT_RECRUITING · PHASE3
• A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer — COMPLETED · PHASE1
• Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer — COMPLETED · PHASE2
• Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer — COMPLETED · PHASE3
• REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer — COMPLETED · PHASE2
• Personalised Disease Monitoring in Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING
• Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) — TERMINATED · PHASE2
• Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer — COMPLETED · NA
• FDG PET/CT in Breast Cancer Bone Mets — ACTIVE_NOT_RECRUITING
• A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) — ACTIVE_NOT_RECRUITING · NA
• The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity — COMPLETED · NA
• Biology Guided Therapy for Breast Cancer for ER Positive — TERMINATED · PHASE2
• Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer — COMPLETED · PHASE1
• A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer — COMPLETED · PHASE2
• [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial — TERMINATED · PHASE1
• Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy — NOT_YET_RECRUITING
• BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer — OTHER · PHASE1
• Pre-operative Immunotherapy Combination Strategies in Breast Cancer — COMPLETED · PHASE2
• Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer — COMPLETED
• Electronic Medical Record-Based Nudge to Reduce SLNB — COMPLETED
• A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older — TERMINATED · NA
• Patterns of Prescribing and Monitoring of Palbociclib — COMPLETED
• Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors — COMPLETED · NA
• Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor — OTHER
• Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer — COMPLETED · PHASE2
• Phase II Study of Everolimus Beyond Progression — TERMINATED · PHASE2
• Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer — COMPLETED · PHASE1
• COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer — WITHDRAWN · PHASE2
• Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer — OTHER · PHASE2
• TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer — COMPLETED · PHASE2
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer — COMPLETED · PHASE2
• Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) — OTHER · PHASE2
• A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene — COMPLETED · PHASE1

Refine this search